Frontiers in nutrition · 2026
Lactiplantibacillus plantarum Probio87 supplementation improves functional constipation and is associated with peripheral gene-expression responses related to inflammation and the gut-brain axis: a randomized, double-blind, placebo-controlled trial.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zheng Fan, Yang Yong, Zhan Yu, Zhang Zhe Wen, Lu Guanting, Xie Daoyuan, Zhang Si-Ming, Mageswary Uma, Lee Yeong-Yeh, Liong Min-Tze
Аннотация
BACKGROUND: Functional constipation is a common disorder of gut-brain interaction that substantially affects bowel function, psychological well-being, and quality of life. Probiotic supplementation represents a microbiota-targeted nutritional strategy for functional constipation, but associated host-response signals remain incompletely understood.
METHODS: This single-center, randomized, double-blind, placebo-controlled trial enrolled 104 adults who met the Rome IV criteria for functional constipation. Participants received either Lactiplantibacillus plantarum Probio87 or placebo for 8 weeks, followed by a 4-week post-intervention follow-up. The primary endpoint was weekly complete spontaneous bowel movements. Secondary outcomes included Rome IV symptom scores, PAC-QOL, HAMD-24, safety parameters, and exploratory whole-blood gene-expression profiles related to inflammation, immune regulation, neuroendocrine signaling, and gut motility. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2300075360).
RESULTS: Probio87 supplementation significantly increased weekly complete spontaneous bowel movements compared with placebo at Week 8 and Week 12. Improvements were also observed in Rome IV symptom scores, constipation-related quality of life, and HAMD-24 domains related to anxiety, sleep, and retardation. Exploratory whole-blood gene-expression analysis showed differential host-response signals after intervention, characterized by increased BDNF expression and reduced expression of IL-1β, CD117, CXCR5, IDO1, DBH, and MLNR in the probiotic group relative to placebo. No intervention-related adverse events or clinically relevant abnormalities in hematological, hepatic, or renal safety parameters were observed.
CONCLUSION: L. plantarum Probio87 supplementation was associated with sustained improvement in bowel function, constipation-related quality of life, and psychological well-being in adults with functional constipation. Exploratory peripheral gene-expression findings suggest that inflammatory, immune, neuroendocrine, and motility-related host-response pathways may be involved, although causal mechanisms require further validation.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/showproj.html?proj=205514, identifier (ChiCTR2300075360).
METHODS: This single-center, randomized, double-blind, placebo-controlled trial enrolled 104 adults who met the Rome IV criteria for functional constipation. Participants received either Lactiplantibacillus plantarum Probio87 or placebo for 8 weeks, followed by a 4-week post-intervention follow-up. The primary endpoint was weekly complete spontaneous bowel movements. Secondary outcomes included Rome IV symptom scores, PAC-QOL, HAMD-24, safety parameters, and exploratory whole-blood gene-expression profiles related to inflammation, immune regulation, neuroendocrine signaling, and gut motility. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2300075360).
RESULTS: Probio87 supplementation significantly increased weekly complete spontaneous bowel movements compared with placebo at Week 8 and Week 12. Improvements were also observed in Rome IV symptom scores, constipation-related quality of life, and HAMD-24 domains related to anxiety, sleep, and retardation. Exploratory whole-blood gene-expression analysis showed differential host-response signals after intervention, characterized by increased BDNF expression and reduced expression of IL-1β, CD117, CXCR5, IDO1, DBH, and MLNR in the probiotic group relative to placebo. No intervention-related adverse events or clinically relevant abnormalities in hematological, hepatic, or renal safety parameters were observed.
CONCLUSION: L. plantarum Probio87 supplementation was associated with sustained improvement in bowel function, constipation-related quality of life, and psychological well-being in adults with functional constipation. Exploratory peripheral gene-expression findings suggest that inflammatory, immune, neuroendocrine, and motility-related host-response pathways may be involved, although causal mechanisms require further validation.
CLINICAL TRIAL REGISTRATION: https://www.chictr.org.cn/showproj.html?proj=205514, identifier (ChiCTR2300075360).